| ANAPTYSBIO INC. DL-,001 |
| USA |
| Gesundheit |
| US0327241065 / A2AJ8C |
| AN6 (Frankfurt) / ANAB (NASDAQ) |
| FRA:AN6, ETR:AN6, AN6:GR, NASDAQ:ANAB |
| - |
| https://www.anaptysbio.co.. |
|
AnaptysBio, Inc. is a biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. AnaptysBio develops and manages antibody-based programs designed to modulate immune pathways involved in chronic immune dysfuncti..
>Volltext.. |
| 1423.03 Mio. EUR |
| 1415.11 Mio. EUR |
| 202.34 Mio. EUR |
| 37.64 Mio. EUR |
| -23.32 Mio. EUR |
| -0.75 EUR |
| 241.49 Mio. EUR |
| 216.34 Mio. EUR |
| 3.9 Mio. EUR |
| 6.87 |
| 107.73% |
| 80.95% |
| - |
| - |
| - |
| - |
| ANAPTYSBIO |
| 22.09.26 |